Literature DB >> 17133186

Vasopressin: mechanisms of action on the vasculature in health and in septic shock.

Lucinda K Barrett1, Mervyn Singer, Lucie H Clapp.   

Abstract

BACKGROUND: Vasopressin is essential for cardiovascular homeostasis, acting via the kidney to regulate water resorption, on the vasculature to regulate smooth muscle tone, and as a central neurotransmitter, modulating brainstem autonomic function. Although it is released in response to stress or shock states, a relative deficiency of vasopressin has been found in prolonged vasodilatory shock, such as is seen in severe sepsis. In this circumstance, exogenous vasopressin has marked vasopressor effects, even at doses that would not affect blood pressure in healthy individuals. These two findings provide the rationale for the use of vasopressin in the treatment of septic shock. However, despite considerable research attention, the mechanisms for vasopressin deficiency and hypersensitivity in vasodilatory shock remain unclear.
OBJECTIVE: To summarize vasopressin's synthesis, physiologic roles, and regulation and then review the literature describing its vascular receptors and downstream signaling pathways. A discussion of potential mechanisms underlying vasopressin hypersensitivity in septic shock follows, with reference to relevant clinical, in vivo, and in vitro experimental evidence. DATA SOURCE: Search of the PubMed database (keywords: vasopressin and receptors and/or sepsis or septic shock) for articles published in English before May 2006 and manual review of article bibliographies. DATA SYNTHESIS AND
CONCLUSIONS: The pathophysiologic mechanism underlying vasopressin hypersensitivity in septic shock is probably multifactorial. It is doubtful that this phenomenon is merely the consequence of replacing a deficiency. Changes in vascular receptors or their signaling and/or interactions between vasopressin, nitric oxide, and adenosine triphosphate-dependent potassium channels are likely to be relevant. Further translational research is required to improve our understanding and direct appropriate educated clinical use of vasopressin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17133186     DOI: 10.1097/01.CCM.0000251127.45385.CD

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  44 in total

Review 1.  Hormones and antioxidant systems: role of pituitary and pituitary-dependent axes.

Authors:  A Mancini; R Festa; V Di Donna; E Leone; G P Littarru; A Silvestrini; E Meucci; A Pontecorvi
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

Review 2.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

Review 3.  [Post-mortem organ donation].

Authors:  T Goroll; G Gerresheim; W Schaffartzik; U Schwemmer
Journal:  Anaesthesist       Date:  2015-07       Impact factor: 1.041

Review 4.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

Review 6.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

7.  Low vasopressin and progression of neonatal sepsis to septic shock: a prospective cohort study.

Authors:  Abhishek S Aradhya; Venkataseshan Sundaram; Naresh Sachdeva; Sourabh Dutta; Shiv S Saini; Praveen Kumar
Journal:  Eur J Pediatr       Date:  2020-02-15       Impact factor: 3.183

8.  cAMP/PKA-dependent increases in Ca Sparks, oscillations and SR Ca stores in retinal arteriolar myocytes after exposure to vasopressin.

Authors:  Owen Jeffries; Mary K McGahon; Peter Bankhead; Maria Manfredi Lozano; C Norman Scholfield; Tim M Curtis; J Graham McGeown
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

9.  Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  Linda G Mellbin; Lars Rydén; Kerstin Brismar; Nils G Morgenthaler; John Ohrvik; Sergiu B Catrina
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

10.  Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Authors:  Alexander R Mackie; Lioubov I Brueggemann; Kyle K Henderson; Aaron J Shiels; Leanne L Cribbs; Karie E Scrogin; Kenneth L Byron
Journal:  J Pharmacol Exp Ther       Date:  2008-02-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.